Clinical Trials

38 enrolled

Lymphoid

Hodgkin Disease

NCT07466927 2026-03-12

Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases

HER2-negative Breast Cancer

NCT07465276 2026-03-11

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

32 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07460206 2026-03-10

PRELUDE

108 enrolled

Carcinoma, Renal Cell

NCT07455032 2026-03-06

Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas

22 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07409844 2026-02-20

RESET C2

152 enrolled

Colonic Neoplasms

NCT07420439 2026-02-19

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

108 enrolled

Lung Diseases, Interstitial

NCT05741164 2026-02-17

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

37 enrolled

Triple Negative Breast Neoplasms

NCT07412054 2026-02-17

BLP-HCC

234 enrolled

Carcinoma, Hepatocellular

NCT07300475 2026-02-13

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Triple Negative Breast Neoplasms

NCT07404332 2026-02-11

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

35 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07360743 2026-02-10

META-1

275 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07385846 2026-02-04

Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency

8 enrolled

Turcot syndrome, Glioblastoma

NCT04266730 2026-01-28

PANDA-VAC

6 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lung Neoplasms

NCT07368985 2026-01-27

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

87 enrolled

Adenocarcinoma, Uterine Cervical Neoplasms

NCT07346053 2026-01-16

Chrono-EVP

224 enrolled

Advanced Bladder Cancer

NCT07347210 2026-01-16

MATVAC-1

98 enrolled

Primary Glioblastoma

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

90 enrolled

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT07290894 2025-12-18

MITO VULVA-01

80 enrolled

Vulvar Neoplasms

NCT06492759 2025-12-16

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

29 enrolled

Phase 1/2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07269158 2025-12-08

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

160 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07264075 2025-12-04

ILLUMINE

780 enrolled

Phase 1/2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07213934 2025-10-15

Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma

40 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07199413 2025-09-30

Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases

20 enrolled

Brain Neoplasms, Meningeal Carcinomatosis

NCT07037004 2025-09-23

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

62 enrolled

Carcinoma, Renal Cell

NCT07178730 2025-09-17

ADAPT-TN-IV

765 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

65 enrolled

Biliary Tract Neoplasms

NCT07129772 2025-09-04

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

53 enrolled

Nasopharyngeal Carcinoma

NCT07090369 2025-07-29

LumOnate

20 enrolled

Prostatic Neoplasms

NCT06951399 2025-07-22

Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT07027124 2025-06-18

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

40 enrolled

Prostatic Neoplasms

NCT06646445 2025-06-13

PREMICES

60 enrolled

Phase 4 Not yet recruiting

Turcot syndrome, Colonic Neoplasms, Microsatellite Instability

NCT07010393 2025-06-08

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

335 enrolled

Thyroid Neoplasms

NCT06894459 2025-04-30

A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma

180 enrolled

Phase 2/3 Not yet recruiting

Head and Neck Neoplasms

NCT06923475 2025-04-11

NEODISCO

150 enrolled

Cholangiocarcinoma, Klatskin Tumor

NCT06045195 2025-04-06

Pembro-FLASH

40 enrolled

Lymphoid

Hodgkin Disease

NCT06749925 2025-04-01

Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma

186 enrolled

Glioblastoma

NCT06814067 2025-02-07

Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma

80 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06805864 2025-02-03

BROTHER

45 enrolled

Uterine Cervical Neoplasms

NCT06793761 2025-01-27

A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCC

260 enrolled

Head and Neck Neoplasms

NCT06706219 2024-12-10

Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Patients With Initially Unresectable Stage III NSCLC

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06692491 2024-11-18

SPRING

200 enrolled

Rare Tumour

NCT06572722 2024-08-27

Perioperative Immunotherapy for NSCLC (ECTOP-1030)

200 enrolled

Phase NA Not yet recruiting

Lung Neoplasms

NCT06549855 2024-08-12

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

10 enrolled

Phase 1/2 Not yet recruiting

Turcot syndrome, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT06484153 2024-07-03

Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

25 enrolled

To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma

NCT06045767 2024-06-03

T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer

Non-small Cell Lung Cancer Metastatic

NCT06411171 2024-05-17

Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:

36 enrolled

Gastroesophageal Junction Cancer

NCT06407310 2024-05-09

Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer

25 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06371807 2024-04-17

KEYPARTNER

20 enrolled